Journal article icon

Journal article

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

Abstract:

Our in-vitro, animal, and early clinical data suggest that tumour necrosis factor alpha (TNF alpha) is an important target for specific biological therapy in rheumatoid arthritis. We report the results of repeated treatment with a chimeric monoclonal antibody to TNF alpha (cA2) in patients having disease flares. 7 patients originally enrolled in an open-label trial completed two to four cycles, each of which was followed by a good clinical response, with median improvements in the swollen-joi...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Role:
Author
Expand authors...
Journal:
Lancet
Volume:
344
Issue:
8930
Pages:
1125-1127
Publication date:
1994-10-05
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
URN:
uuid:581fdb8d-cd33-4192-8cc1-826fdbc0246b
Source identifiers:
481655
Local pid:
pubs:481655

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP